Table 2 Subgroup analysis of the seroprotection rate after HBV vaccination among children under 5 years in Africa
From: Immune response to hepatitis B vaccine among children under 5 years in Africa: a meta-analysis
Subgroups | Number of studies | Sample size | Pooled rate (95% CI) | I2 (p value) | p value (subgroup differences) |
|---|---|---|---|---|---|
Region | Â | Â | Â | Â | Â |
North | 3 | 1343 | 80.69% (62.87–93.81%) | NC | 0.232 |
West and Central | 14 | 4019 | 88.15% (82.49–92.85%) | 95.86 (< 0.01) |  |
East and Southern | 12 | 3805 | 92.01% (86.95–95.95%) | 95.85 (< 0.01) |  |
Assay method | Â | Â | Â | Â | Â |
Enzyme immunoassay | 19 | 6229 | 85.07% (81.20–88.58%) | 93.53 (< 0.01) |  < 0.001 |
Radioimmunoassay | 4 | 1189 | 92.73% (77.69–80.49%) | 97.66 (< 0.01) |  |
Chemiluminescence assay | 4 | 1067 | 97.61% (94.30–99.60%) | 83.53 (< 0.01) |  |
Immunofluorescence assay | 2 | 682 | 97.27% (95.88–98.40%) | NC |  |
Vaccine dose | Â | Â | Â | Â | Â |
Three doses | 28 | 8586 | 89.00% (85.37–92.17%) | 95.84 (< 0.01) | 0.005 |
Four doses | 5 | 464 | 97.17% (93.29–99.62%) | 57.11 (0.05) |  |
Vaccine combination | Â | Â | Â | Â | Â |
Monovalent | 9 | 2989 | 94.04% (87.80–98.20%) | 97.12% (< 0.01) |  < 0.001 |
Hexavalent | 2 | 283 | 95.55% (92.71–97.76%) | NC |  |
Pentavalent | 11 | 2875 | 83.87% (78.04–88.97%) | 93.18% (< 0.01) |  |
Heptavalent | 1 | 117 | 88.03% (80.91–92.74%) | NA |  |
Tetravalent | 1 | 279 | 71.68% (66.13–76.65%) | NA |  |
Vaccine type | Â | Â | Â | Â | Â |
Recombinant | 20 | 6422 | 89.06% (84.29–93.09%) | 96.69% (< 0.01) | 0.405 |
Plasma-derived | 5 | 1606 | 91.92% (87.26–95.65%) | 83.62% (< 0.01) |  |